SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,984.56645577 USD and is down -1.38 over the last 24 hours. It is currently trading on 12773 active market(s) with $23,404,967,729.76 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins slide toward key support is drawing attention amid traders concerns about the reported Binance hack and other exchange security incidents, alongside talk of ETF outflows and long liquidations. Bears warn of further downside, while bulls argue the price is holding up and view the dip as accumulation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY discussion centers on a broad market pullback, with traders pointing to weakness in AI and tech stocks, midterm-election uncertainty, and conflicting signals around U.S.-Iran strikes and diplomacy. Bearish calls for further declines compete with expectations of an oversold bounce or relief rally if tensions ease.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,883,313.16514313 with 590,206,315.78603745 in circulation. The last known price of Solana is 92.37097662 USD and is down -1.79 over the last 24 hours. It is currently trading on 1189 active market(s) with $2,843,805,655.98 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solanas slide through a key psychological support amid broader crypto weakness is driving bearish chart talk, with traders watching for further downside. The Binance security incident has added to market-wide confidence concerns, though some traders say SOL was already under pressure; views remain split between shorting or expecting more losses and buying the dip to stake.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,665,205.855202 with 36,823,860,963.224877 in circulation. The last known price of Cardano is 0.18956469 USD and is down -1.68 over the last 24 hours. It is currently trading on 1752 active market(s) with $215,011,959.13 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

Cardano is drawing attention amid a weak crypto market, with traders flagging bearish technical signals and lost support while others view the decline as a buying opportunity and expect a rebound. Sentiment is sharply divided between claims that ADA could keep sliding and speculative hopes for a breakout or short squeeze.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs upcoming earnings and guidance are in focus after Intels weak outlook helped drive a broader semiconductor selloff, raising questions about whether chip demand concerns extend to AMD. Traders are split between expecting strong data-center results to ease those fears and worrying that high expectations, AI-stock weakness, and a cautious outlook could weigh on the shares even after a beat.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs steep slide toward fresh lows is driving bearish frustration, with traders pointing to its sensitivity to Bitcoin and a lack of announced AI/data-center tenants as reasons for weak sentiment. Bulls argue the stock is oversold and speculate that tenant deals around the upcoming earnings report could improve the outlook, while others doubt the pivot will deliver.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A strong fiscal first-quarter report, with substantial beats on revenue and earnings and raised full-year revenue guidance, has driven renewed attention to Aehrs AI-chip testing demand. Bulls applaud the results and after-hours rebound, while skeptics question whether gains will hold amid a weak market and concerns about the stocks valuation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Midterm-election uncertainty is dominating DJT trading chatter, with traders debating whether the stocks bounce near support can continue or whether election-related disappointment will bring another selloff. Bulls point to oversold conditions and a possible political tailwind, while bears call the move speculative and question the companys fundamentals; Iran-war headlines also feature in broader market-risk discussion.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention mainly for persistent share-price weakness and investor frustration with management, dilution, and the Astria acquisition. Bulls point to ORLADEYO growth and future pipeline readouts, especially navenibart, while skeptics argue those catalysts are distant and want clearer evidence that growth will benefit shareholders.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong Q3 results and raised outlook, driven by rapid commercial AI growth, are drawing attention, but the stock fell despite the beat. Traders are debating whether its high valuation already reflects that growth, with some also flagging slower contract-value growth and broader weakness in AI stocks.

statis crypto Watchlist

Ethereum

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$DARE 💡👀💡Why the ARPA-H LaunchPad award for Daré Bioscience may be more important than the market currently realizes.

1/ Daré was selected by ARPA-H’s LaunchPad program and can receive up to $10M in milestone-based, non-dilutive funding to advance DARE-HPV. LaunchPad is designed for technologies approaching commercialization—not early-stage academic research.

2/ ARPA-H is modeled after DARPA and is highly selective. Being chosen signals that the U.S. government sees both significant clinical impact and real-world deployment potential.

3/ The support goes beyond funding. Daré also receives commercialization guidance through the LaunchPad Accelerator and collaboration with an Entrepreneur-in-Residence focused on bringing the technology to market.

https://arpa-h.gov/explore-funding/initiatives-and-sprints/sprint-for-womens-health

The Advanced Research Projects Agency for Health (ARPA-H) supports transformative research to drive biomedical and health breakthroughs ranging from molecular to societal to provide transformative health solutions for all.

ARPA-H

Sprint for Women's Health

$DARE 💡🎯💡📈🕛
9/ The overlooked point for investors: ARPA-H support provides non-dilutive funding, scientific validation, and commercialization infrastructure—all of which significantly de-risk development.

10/ For a small biotech, that combination—government validation + funding + commercialization support—can meaningfully improve the probability of bringing a new therapy to market.

StockTwits for iOS

BuyAndHold

Dare Bioscience Inc

 💡👀💡Why the ARPA-H LaunchPad award for Daré Bioscience may be more important than the market currently realizes.

1/ Daré was selected by ARPA-H’s LaunchPad program and can receive up to $10M in milestone-based, non-dilutive funding to advance DARE-HPV. LaunchPad is designed for technologies approaching commercialization—not early-stage academic research.

2/ ARPA-H is modeled after DARPA and is highly selective. Being chosen signals that the U.S. government sees both significant clinical impact and real-world deployment potential.

3/ The support goes beyond funding. Daré also receives commercialization guidance through the LaunchPad Accelerator and collaboration with an Entrepreneur-in-Residence focused on bringing the technology to market.



5/ Today, women with persistent HPV infections are often placed in “watchful waiting,” involving repeated doctor visits, monitoring, and sometimes invasive procedures if abnormalities develop. There is currently no approved drug that clears persistent hrHPV infections.

6/ DARE-HPV aims to change this paradigm. It is a vaginal soft-gel insert containing the well-known antiretroviral drugs lopinavir and ritonavir, designed to allow women to treat persistent high-risk HPV infections at home.

7/ By intervening earlier in the disease pathway, this approach could potentially eliminate prolonged monitoring and reduce the need for invasive procedures.

8/ If successful, this model could transform HPV management by enabling early, at-home treatment—reducing healthcare costs and improving access to care, especially for women facing geographic, socioeconomic, or healthcare system barriers.

9/ The overlooked point for investors: ARPA-H support provides non-dilutive funding, scientific validation, and commercialization infrastructure—all of which significantly de-risk development.

10/ For a small biotech, that combination—government validation + funding + commercialization support—can meaningfully improve the probability of bringing a new therapy to market.